ESMO 2022 | Unmet needs in nonmelanoma skin cancer

Current treatment strategies for nonmelanoma skin cancer (NMSC) has predominantly revolved around checkpoint blockades, with avelumab being approved for Merkel cell carcinoma and cemiplimab approved for advanced basal cell carcinoma and squamous cell carcinoma. Dirk Schadendorf, MD, University Hospital Essen, Essen, Germany, gives an overview of current unanswered questions in the field of NMSC. Half of patients tend to not benefit from current treatments and further research is needed to overcome resistance to PD-1 inhibitors as well as find strategies to manage immunosuppression in patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.